Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1322

1.

Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD-1 Expression Levels and PD-1 Receptor Occupancy by Nivolumab and Pembrolizumab.

Pluim D, Ros W, Miedema IHC, Beijnen JH, Schellens JHM.

Cytometry A. 2019 Aug 12. doi: 10.1002/cyto.a.23873. [Epub ahead of print]

PMID:
31407460
2.

Development and validation of an LC-MS/MS method with a broad linear dynamic range for the quantification of tivozanib in human and mouse plasma, mouse tissue homogenates, and culture medium.

Bruin MAC, Rosing H, Lucas L, Wang J, Huitema ADR, Schinkel AH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Sep 1;1125:121723. doi: 10.1016/j.jchromb.2019.121723. Epub 2019 Jul 18.

PMID:
31352204
3.

P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.

Martínez-Chávez A, van Hoppe S, Rosing H, Lebre MC, Tibben M, Beijnen JH, Schinkel AH.

Mol Pharm. 2019 Aug 5. doi: 10.1021/acs.molpharmaceut.9b00475. [Epub ahead of print]

PMID:
31329454
4.

A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Janssen JM, Dorlo TPC, Niewerth D, Wilhelm AJ, Zwaan CM, Beijnen JH, Attarbaschi A, Baruchel A, Fagioli F, Klingebiel T, De Moerloose B, Palumbo G, von Stackelberg A, Kaspers GJL, Huitema ADR.

Clin Pharmacokinet. 2019 Jul 16. doi: 10.1007/s40262-019-00803-y. [Epub ahead of print]

PMID:
31313068
5.

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes.

van Eijk M, Boosman RJ, Schinkel AH, Huitema ADR, Beijnen JH.

Cancer Chemother Pharmacol. 2019 Sep;84(3):487-499. doi: 10.1007/s00280-019-03905-3. Epub 2019 Jul 15. Review.

6.

P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.

Li W, Tibben M, Wang Y, Lebre MC, Rosing H, Beijnen JH, Schinkel AH.

Int J Cancer. 2019 Jul 15. doi: 10.1002/ijc.32568. [Epub ahead of print]

PMID:
31304590
7.

Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma.

Janssen JM, de Vries N, Venekamp N, Rosing H, Huitema ADR, Beijnen JH.

J Pharm Biomed Anal. 2019 Sep 10;174:561-566. doi: 10.1016/j.jpba.2019.06.034. Epub 2019 Jun 24.

PMID:
31255856
8.

Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant.

van Nuland M, Janssen JM, van Hoek B, Rosing H, Beijnen JH, Bergman AM.

Clin Genitourin Cancer. 2019 May 30. pii: S1558-7673(19)30176-4. doi: 10.1016/j.clgc.2019.05.026. [Epub ahead of print] No abstract available.

PMID:
31248829
9.

A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir.

de Weger VA, Stuurman FE, Koolen SLW, Moes JJ, Hendrikx JJMA, Sawicki E, Thijssen B, Keessen M, Rosing H, Mergui-Roelvink M, Huitema ADR, Nuijen B, Beijnen JH, Schellens JHM, Marchetti S.

Clin Cancer Res. 2019 Jun 19. doi: 10.1158/1078-0432.CCR-17-2299. [Epub ahead of print]

PMID:
31217201
10.

Bioanalytical LC-MS/MS validation of therapeutic drug monitoring assays in oncology.

van Nuland M, Rosing H, Schellens JHM, Beijnen JH.

Biomed Chromatogr. 2019 Jun 18:e4623. doi: 10.1002/bmc.4623. [Epub ahead of print] Review.

PMID:
31215049
11.

Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence.

Braal CL, Beijnen JH, Koolen SLW, Oomen-de Hoop E, Steeghs N, Jager A, Huitema ADR, Mathijssen RHJ.

J Clin Oncol. 2019 Aug 1;37(22):1980-1981. doi: 10.1200/JCO.19.00418. Epub 2019 Jun 18. No abstract available.

PMID:
31211599
12.

Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry.

Martínez-Chávez A, Rosing H, Hillebrand M, Tibben M, Schinkel AH, Beijnen JH.

Anal Bioanal Chem. 2019 Aug;411(20):5331-5345. doi: 10.1007/s00216-019-01932-w. Epub 2019 Jun 17.

13.

Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials.

Crombag MBS, Haanen JBAG, Baas P, Beijnen JH, Huitema ADR.

J Geriatr Oncol. 2019 Jun 14. pii: S1879-4068(19)30118-3. doi: 10.1016/j.jgo.2019.06.001. [Epub ahead of print] No abstract available.

PMID:
31208830
14.

Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).

van Hoppe S, Jamalpoor A, Rood JJM, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.

Pharmacol Res. 2019 Aug;146:104297. doi: 10.1016/j.phrs.2019.104297. Epub 2019 Jun 5.

PMID:
31175939
15.

Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine.

Groenland SL, Mathijssen RHJ, Beijnen JH, Huitema ADR, Steeghs N.

Eur J Clin Pharmacol. 2019 Sep;75(9):1309-1318. doi: 10.1007/s00228-019-02704-2. Epub 2019 Jun 7.

PMID:
31175385
16.

Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

Sparidans RW, Li W, Schinkel AH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Aug 1;1122-1123:78-82. doi: 10.1016/j.jchromb.2019.05.026. Epub 2019 May 27.

17.

Use of leftovers of monoclonal antibody products after partial extraction - A microbiological safety study.

Arnamo AH, Huitema AD, Beijnen JH, Nuijen B.

J Oncol Pharm Pract. 2019 Jun 2:1078155219850297. doi: 10.1177/1078155219850297. [Epub ahead of print]

PMID:
31156055
18.

Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review.

van Bussel MTJ, Beijnen JH, Brandsma D.

BMC Cancer. 2019 May 30;19(1):519. doi: 10.1186/s12885-019-5741-y.

19.

Liquid chromatography-tandem mass spectrometric assay for the quantification of galunisertib in human plasma and the application in a pre-clinical study.

Tibben MM, Huijberts S, Li W, Schinkel AH, Gebretensae A, Rosing H, Beijnen JH.

J Pharm Biomed Anal. 2019 Sep 5;173:169-175. doi: 10.1016/j.jpba.2019.05.037. Epub 2019 May 21.

PMID:
31146172
20.

Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation.

Palić S, Bhairosing P, Beijnen JH, Dorlo TPC.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e02507-18. doi: 10.1128/AAC.02507-18. Print 2019 Jul.

21.

Predictive Value of Microdose Pharmacokinetics.

van Nuland M, Rosing H, Huitema ADR, Beijnen JH.

Clin Pharmacokinet. 2019 Apr 27. doi: 10.1007/s40262-019-00769-x. [Epub ahead of print] Review.

PMID:
31030372
22.

LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide.

van Nuland M, Venekamp N, Wouters WME, van Rossum HH, Rosing H, Beijnen JH.

J Pharm Biomed Anal. 2019 Jun 5;170:161-168. doi: 10.1016/j.jpba.2019.03.043. Epub 2019 Mar 20.

PMID:
30925273
23.

Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

Dogan-Topal B, Li W, Schinkel AH, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 15;1110-1111:116-123. doi: 10.1016/j.jchromb.2019.02.017. Epub 2019 Feb 16.

24.

Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort.

de Vries Schultink AHM, Crombag MBS, van Werkhoven E, Otten HM, Bergman AM, Schellens JHM, Huitema ADR, Beijnen JH.

Cancer Med. 2019 Apr;8(4):1406-1415. doi: 10.1002/cam4.2003. Epub 2019 Feb 22.

25.

Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite β‑decitabine in human plasma, whole blood and urine.

Roosendaal J, Wang K, Rosing H, Lucas L, Gebretensae A, Oganesian A, Schellens JHM, Beijnen JH, Lin ZJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 1;1109:132-141. doi: 10.1016/j.jchromb.2019.01.011. Epub 2019 Jan 22.

PMID:
30754019
26.

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.

Crombag MBS, de Vries Schultink AHM, van Doremalen JGC, Otten HM, Bergman AM, Schellens JHM, Beijnen JH, Huitema ADR.

Drugs Aging. 2019 Apr;36(4):379-385. doi: 10.1007/s40266-019-00643-2.

PMID:
30734241
27.

ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation.

Durmus S, van der Valk M, Teunissen SF, Song JY, Wagenaar E, Beijnen JH, Schinkel AH.

Arch Toxicol. 2019 Mar;93(3):775-790. doi: 10.1007/s00204-019-02394-w. Epub 2019 Jan 30.

PMID:
30701287
28.

Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.

Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.

Eur J Pharm Biopharm. 2019 Mar;136:120-130. doi: 10.1016/j.ejpb.2019.01.016. Epub 2019 Jan 17.

PMID:
30660696
29.

Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology.

van Nuland M, Venekamp N, de Vries N, de Jong KAM, Rosing H, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Feb 1;1106-1107:26-34. doi: 10.1016/j.jchromb.2019.01.001. Epub 2019 Jan 3.

30.

Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis.

van Nuland M, Groenland S, Bergman AM, Rotmans JI, Rosing H, Beijnen JH, Huitema ADR.

Clin Genitourin Cancer. 2019 Apr;17(2):e383-e386. doi: 10.1016/j.clgc.2018.12.004. Epub 2018 Dec 19. No abstract available.

31.

Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study.

Crombag MBS, de Vries Schultink AHM, Koolen SLW, Wijngaard S, Joerger M, Schellens JHM, Dorlo TPC, van Erp NP, Mathijssen RHJ, Beijnen JH, Huitema ADR.

Pharm Res. 2019 Jan 7;36(2):33. doi: 10.1007/s11095-018-2563-6.

PMID:
30617624
32.

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.

Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM.

Ann Oncol. 2019 Feb 1;30(2):219-235. doi: 10.1093/annonc/mdy551.

PMID:
30608567
33.

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.

Wang J, Gan C, Retmana IA, Sparidans RW, Li W, Lebre MC, Beijnen JH, Schinkel AH.

Int J Pharm. 2019 Feb 10;556:172-180. doi: 10.1016/j.ijpharm.2018.12.014. Epub 2018 Dec 12.

PMID:
30553002
34.

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, van Werkhoven E, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Eur J Cancer. 2019 Jan;107:60-67. doi: 10.1016/j.ejca.2018.11.010. Epub 2018 Dec 11.

PMID:
30544060
35.

Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling.

Verheijen RB, Thijssen B, Atrafi F, Schellens JHM, Rosing H, de Vries N, Beijnen JH, Mathijssen RHJ, Steeghs N, Huitema ADR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jan 1;1104:234-239. doi: 10.1016/j.jchromb.2018.11.030. Epub 2018 Nov 30.

PMID:
30530116
36.

Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.

Henricks LM, van Merendonk LN, Meulendijks D, Deenen MJ, Beijnen JH, de Boer A, Cats A, Schellens JHM.

Int J Cancer. 2019 May 1;144(9):2347-2354. doi: 10.1002/ijc.32022. Epub 2019 Jan 4.

PMID:
30485432
37.

Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

Sparidans RW, Wang Y, Schinkel AH, Schellens JHM, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Dec 1;1102-1103:167-172. doi: 10.1016/j.jchromb.2018.10.023. Epub 2018 Oct 30.

38.

Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid.

Pluim D, Ros W, van Bussel MTJ, Brandsma D, Beijnen JH, Schellens JHM.

J Pharm Biomed Anal. 2019 Feb 5;164:128-134. doi: 10.1016/j.jpba.2018.10.025. Epub 2018 Oct 17.

PMID:
30368118
39.
40.

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.

PMID:
30348537
41.

Development and validation of a quantitative method for thymidine phosphorylase activity in peripheral blood mononuclear cells.

Jacobs BAW, Pluim D, van der Laan P, Tzani A, Beijnen JH, Schellens JHM.

Nucleosides Nucleotides Nucleic Acids. 2018;37(8):436-454. doi: 10.1080/15257770.2018.1498270. Epub 2018 Oct 4.

PMID:
30285552
42.

Impact of age on exposure to oral antiandrogen therapies in clinical practice.

Crombag MBS, van Nuland M, Bergman AM, Rosing H, Schellens JHM, Huitema ADR, Beijnen JH.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):168-175. doi: 10.1038/s41391-018-0096-z. Epub 2018 Oct 2.

PMID:
30279580
43.

P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.

Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.

Pharmacol Res. 2018 Nov;137:47-55. doi: 10.1016/j.phrs.2018.09.020. Epub 2018 Sep 22.

PMID:
30253203
44.

ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.

de Gooijer MC, Buil LCM, Çitirikkaya CH, Hermans J, Beijnen JH, van Tellingen O.

Mol Pharm. 2018 Nov 5;15(11):5236-5243. doi: 10.1021/acs.molpharmaceut.8b00742. Epub 2018 Oct 5.

PMID:
30252484
45.

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.

van Hoppe S, Rood JJM, Buil L, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.

Mol Pharm. 2018 Nov 5;15(11):5124-5134. doi: 10.1021/acs.molpharmaceut.8b00702. Epub 2018 Oct 10.

PMID:
30247919
46.

Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.

de Vries Schultink AHM, Huitema ADR, Beijnen JH.

Breast. 2018 Dec;42:38-40. doi: 10.1016/j.breast.2018.08.100. Epub 2018 Aug 22.

PMID:
30153552
47.

Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates.

Sparidans RW, Li W, Schinkel AH, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2018 Nov 30;161:136-143. doi: 10.1016/j.jpba.2018.08.038. Epub 2018 Aug 19.

PMID:
30149189
48.

Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter?

Crombag MBS, van Doremalen JGC, Janssen JM, Rosing H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR.

Br J Clin Pharmacol. 2018 Dec;84(12):2770-2778. doi: 10.1111/bcp.13725. Epub 2018 Sep 26.

PMID:
30068020
49.

Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers.

Henricks LM, Jacobs BAW, Meulendijks D, Pluim D, van den Broek D, de Vries N, Rosing H, Beijnen JH, Huitema ADR, Guchelaar HJ, Cats A, Schellens JHM.

Br J Clin Pharmacol. 2018 Dec;84(12):2761-2769. doi: 10.1111/bcp.13719. Epub 2018 Sep 25.

50.

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment.

van Andel L, Rosing H, Schellens JH, Beijnen JH.

Mar Drugs. 2018 Jul 23;16(7). pii: E246. doi: 10.3390/md16070246. Review.

Supplemental Content

Loading ...
Support Center